

Kemin Biologics Holds 2026 Respiratory Integrity Forum Highlighting Emerging Newcastle Disease Genotype VII

Event demonstrates Kemin's vaccine business unit's expertise and solutions for one of the poultry industry's most pressing challenges

ROTTERDAM, Netherlands (August 11, 2026)— Kemin Biologics, the vaccine business unit of Kemin Industries, a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services by 2042, recently hosted the 2026 Respiratory Integrity Forum, a scientific exchange focused on one of the poultry industry's most pressing challenges: emerging Newcastle Disease Virus (NDV) Genotype VII.

Kemin Biologics held the third session of the event—moderated by *Poultry World*—in Rotterdam, Netherlands, on June 9, and highlighted how collaboration, applied science, and practical field experience can help support stronger respiratory health strategies for producers worldwide.

Kemin Biologics presented its NDV homologous vaccine solutions designed to support early protection against respiratory and enteric challenges associated with NDV Genotype VII. The NDV homologous vaccine solutions feature:

- Genotype-matched protection against circulating NDV Genotype VII strains
- Significant reduction in viral shedding to help limit transmission
- A flexible vaccine range combining live and inactivated solutions for more comprehensive immunity over time

The forum also featured respected voices in poultry health, including Professor Kannan Ganapathy of the University of Liverpool and Dr. Abdallah Makahleh, Global Technical Services Manager, Kemin Biologics. The speakers' perspectives reinforced the value of combining academic expertise with real-world field insight to address evolving disease threats and improve vaccination decision-making across poultry industry segments.

The third session of the Respiratory Integrity Forum demonstrated Kemin Biologics' continued commitment to advancing poultry health through innovation, partnership, and vaccination best practices. By bringing together global insights and practical solutions, the 2026 Respiratory Integrity Forum reflected Kemin Biologics' role in helping the industry navigate complex Newcastle Disease challenges with confidence, credibility, and a strong focus on producer needs.

[Click here](#) to watch 2026 Respiratory Integrity Forum.

[Click here](#) to read more about Kemin Biologics in *Poultry World*.

###

About Kemin Industries

Kemin Industries (www.kemin.com) is a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services. The company supplies over 500 specialty ingredients for human and animal health and nutrition, pet food, aquaculture, nutraceutical, food technologies, textile, biofuel, and animal vaccine industries.

For over half a century, Kemin has been dedicated to using applied science to address industry challenges and offer product solutions to customers in more than 120 countries. Kemin provides ingredients to feed a growing population with its commitment to the quality, safety, and efficacy of food, feed, and health-related products.

Established in 1961, Kemin is a privately held, family-owned-and-operated company with more than 4,000 global employees and operations in 90 countries, including manufacturing facilities in Belgium, Brazil, China, Egypt, India, Italy, Singapore, South Africa, and the United States.

Media Contact:

Francisco Monsalve, Global Brand Manager, Kemin Biologics | francisco.monsalve@kemin.com, +49 4722 909 4445



Kemin Biologics engaged a global audience to address emerging NDV Genotype VII at the 2026 Respiratory Integrity Forum.

<https://news.kemin.com/press-releases?item=122723>